Bruder Consulting & Venture Group

BCVG advisor, Ali Mobasheri, worked with our client partner KTG to demonstrate TissueGene-C, a cell and gene therapy, TG-C induces the polarization of M2 macrophages and the upregulation of IL-10 and IL-1ra while inhibiting TNF-a expression. This technology is currently being evaluated in a Phase III clinical trial. How can the experts at BCVG support your vision? Connect with us today! #regenerativemedicine #BCVG #KTG #ClientPartners Read the full article in the comments below.

Check out this recent publication by BCVG advisor, William (Bill) Walsh. Physicians are using 3-D printed implants, including intervertebral cages, with increasing frequency. This publication showed use of a bone graft in these cages is critical to achieve successful fusion in the sheep model. Image: Figure 4 shows bony fusion with different cage designs filled with iliac crest bone graft in A-C, where an empty cage in panel D shows little bone formation. Read the full article with link in comments below. How can we help your business accelerate forward? Connect with the experts at BCVG today. DM us for details or visit our website. #regenerativemedicine #BCVG #bonegraft #3dprinted

Notable developments catching our attention this week: 1. BioRestorative Therapies received IND clearance to begin a Phase 2 clinical trial with BRTX-100 for chronic cervical discogenic pain 2. Pacira BioSciences acquired GQ Bio, a clinical-stage developer of gene therapies for osteoarthritis and intervertebral disc degeneration 3. Atreon Orthopedics announced its BioCharge Matrix received 510(k) clearance for use in rotator cuff repair Let BCVG help you make sense of the market. Direct message (DM) with BCVG to learn more! #BioRestorative, #Pacira, #osteoarthritis, #rotatorcuff, #regenerativemedicine, #BCVG

BCVG is pleased to announce that Scott Bruder, MD, PhD has been named to the American Academy of Orthopaedic Surgeons (AAOS) Committee On Devices, Biologics, and Technology, effective immediately.  The Mission of the Committee is to: 1) Influence all aspects of orthopaedic devices, biologics, and technologies with respect to regulatory, industrial and payors affairs. 2) Provide the fellowship with evidence-based resources, quality, and value assessments to distill the current state of evidence and equip membership with resources that assist with making informed decisions, and facilitating the safe and effective use of devices, biologics, and technologies to treat musculoskeletal disorders in patients.  Dr. Bruder previously served on the AAOS Basic Science Education Committee with Dr. Roy Aaron, his long-time collaborator of more than 40 years, and with whom he edited the first AAOS Textbook on “Orthobiologics” in 2024." #BCVG #AAOS #Biologics #DrRoyAaron #Orthobiologics Read more on the committee with the link in comments below.

#DidYouKnow Dr. John P. Fisher’s lab is advancing the field of 3-D bioprinting. Check out their recent publication, wherein their anion-mediated gel shrinking reduced the printing resolution to 70um while maintaining up to 100% cast cell viability and gel compressive and storage modulus. Read the full article in our comments section. How can BCVG support you today? Connect with us! #medtech #biotech #managementconsulting #tissueengineering #IntegratedInsights #bioprinting 

Are you concerned about how changes at FDA will impact the review and approval of your new biologic, drug, device, HCT/P or combination product? Reach out for guidance and support by our team of experts and former FDA leaders.

Notable developments catching our attention this week: Medtronic acquired intellectual property rights to nanosurface technology from Nanovis for use in spine fusion procedures StemSight received €2.3 MM in funding to continue developing its iPS cell therapy to treat blindness caused by limbal stem cell deficiency Lineage Cell Therapeutics initiated a clinical study to evaluate its OPC1 cell therapy for spinal cord injury Let BCVG help you make sense of the market. Message us to learn more! #Medtronic  #nanotechnology #StemSight #regenerativemedicine #BCVG

#ICYMI Check out this article by Dr. Liisa Kuhn’s lab at the University of Connecticut Tricolor Transgenic Murine Model for Studying Growth Plate Injury Growth plates are vital to limb lengthening in infants, toddlers, and teens. However, these weaker areas in the bone can fracture with even mild trauma.   Kuhn’s team has advanced the field of growth plate research by developing a unique mouse model that avoids cartilage damage and allows for longitudinal analysis through imaging. To read the article, check out the link in the comments below. Let BCVG help you make sense of the market. Direct message us to learn more!  #regenerativemedicine #BCVG #growthplates #UniversityofConnecticut

Congratulations to BCVG client partner OssiFi Therapeutics on this excellent press. It’s great to see a technology focused on treating a rare disease such as osteogenesis imperfecta.   Read the full article in the comments below. How can we support your work? Connect with us via our website or DM us today!  #regenerativemedicine #BCVG #ClientPartners

Notable developments catching our attention this week: 1. Novadip Biosciences announced a 100% fusion rate with its cell-free NVD-X3 bone grafting technology in wrist fractures 2. Doron Therapeutics received RMAT designation from the FDA for MOTYS, its investigational treatment for knee osteoarthritis 3. BioRestorative Therapies received Fast Track designation for BRTX-100 in the management of chronic lumbar disc disease Let BCVG help you make sense of the market. Direct message us to learn more! #Novadip #BioRestorative #orthopedics  #regenerativemedicine #BCVG